Cumberland Pharmaceuticals Inc.
CPIX
$4.76
$0.235.08%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.21% | -7.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.86% | -7.75% | |||
| Cost of Revenue | 49.40% | -22.67% | |||
| Gross Profit | 8.97% | -4.61% | |||
| SG&A Expenses | 6.73% | 0.96% | |||
| Depreciation & Amortization | 35.34% | -1.96% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.89% | -0.88% | |||
| Operating Income | -8.71% | -65.03% | |||
| Income Before Tax | -28.39% | -39.80% | |||
| Income Tax Expenses | -600.00% | 0.00% | |||
| Earnings from Continuing Operations | -23.72% | -39.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 69.01% | -141.76% | |||
| Net Income | -23.30% | -42.23% | |||
| EBIT | -8.71% | -65.03% | |||
| EBITDA | 40.25% | -612.77% | |||
| EPS Basic | -24.02% | -42.91% | |||
| Normalized Basic EPS | -11.28% | -67.52% | |||
| EPS Diluted | -27.45% | -37.50% | |||
| Normalized Diluted EPS | -11.28% | -67.52% | |||
| Average Basic Shares Outstanding | -0.58% | -0.46% | |||
| Average Diluted Shares Outstanding | -0.58% | -0.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||